IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A liquid formulation comprising

- a) a growth hormone, or a substance, which stimulates release or potentiates the activity of endogenous hGH;
 - b) polyethylene-polypropylene glycol;
 - c) a citrate buffer; and
 - d) a stabilizer.

Claim 2 (Original): The formulation according to claim 1, wherein the growth hormone is human growth hormone.

Claim 3 (Original): The formulation according to claim 1, wherein the substance, which stimulates release or potentiates the activity of endogenous hGH, is growth hormone releasing hormone (GHRH).

Claim 4 (Currently Amended): The formulation according to any of the preceding elaims claim 1, wherein the stabilizer is sucrose.

Claim 5 (Currently Amended): The formulation according to claim 4, comprising sucrose in a concentration ranging from 10 mg/ml to 100 mg/ml or 20 mg/ml to 80 mg/ml or about 60 mg/ml.

Preliminary Amendment

Claim 6 (Currently Amended): The formulation according to any of the preceding elaims claim 1, comprising citrate in a concentration ranging from 1 to 100 mM or from 5 to 50 mM or from 10 to 20 mM.

Claim 7 (Currently Amended): The formulation according to any of the preceding elaims claim 1, having a pH in the range of 5 to 7 or 5.5 to 6.5 or about 6.

Claim 8 (Currently Amended): The formulation according to any of the preceding elaims claim 1, comprising the polyethylene-polypropylene glycol in a concentration ranging from 0.5 to 5 mg/ml or 1 to 2 mg/ml or 1.5 mg/ml.

Claim 9 (Currently Amended): The formulation according to any of the preceding elaims claim 1, wherein the polyethylene-polypropylene glycol is a pluronic polyol.

Claim 10 (Original): The formulation according to claim 9, wherein the pluronic polyol is pluronic F68.

Claim 11 (Currently Amended): The formulation according to any of the preceding elaims claim 1, further comprising a preservative.

Claim 12 (Currently Amended): A formulation according to claim 11, comprising the preservative in a concentration ranging from 1 to 10 mg/ml or 2 to 5 mg/ml or 3 mg/ml.

Claim 13 (Currently Amended): The formulation according to claim 11 or 12, wherein the preservative is phenol.

Claim 14 (Currently Amended): The formulation according to any of the preceding elaims claim 1, said the formulation having a pH of 5.9 and consisting of r-hGH, sucrose, Poloxamer 188, citric acid and/or citrate buffer and optionally water for injection.

Claim 15 (Currently Amended): The formulation according to any of the preceding elaims claim 1, said the formulation having a pH of 5.9 and consisting of r-hGH, sucrose, Poloxamer 188, citric acid, phenol and optionally water for injection.

Claim 16 (Currently Amended): A process for production of a liquid formulation according to any of the preceding claims claim 1, comprising the step of preparing an aqueous solution of the components of (a) to (d).

Claim 17 (Currently Amended): A process for the production of a liquid formulation according to any of claims 1 to 15 claim 1, comprising the step of placing a predetermined amount of the formulation into a sterile container.

Claim 18 (Currently Amended): A pharmaceutical composition comprising the formulation according to any of claims 1 to 15 claim 1.

Claim 19 (Currently Amended): A form of presentation of the <u>The</u> liquid formulation according to any of claims 1 to 13 claim 1, wherein the formulation is hermetically closed in a sterile condition within a container suited for storage before use.

277219US0PCT

Preliminary Amendment

Claim 20 (New): The formulation according to claim 4, comprising sucrose in a concentration ranging from 20 mg/ml to 80 mg/ml.

Claim 21 (New): The formulation according to claim 4, comprising sucrose in a concentration at about 60 mg/ml.

Claim 22 (New): The formulation according to claim 1, comprising citrate in a concentration ranging from 5 to 50 mM.

Claim 23 (New): The formulation according to claim 1, comprising citrate in a concentration ranging from 10 to 20 mM.

Claim 24 (New): The formulation according to claim 1, having a pH in the range of 5.5 to 6.5.

Claim 25 (New): The formulation according to claim 1, having a pH at about 6.

Claim 26 (New): The formulation according to claim 1, comprising the polyethylene-polypropylene glycol in a concentration ranging from 1 to 2 mg/ml.

Claim 27 (New): The formulation according to claim 1, comprising the polyethylene-polypropylene glycol in a concentration at 1.5 mg/ml.

Claim 28 (New): A formulation according to claim 11, comprising the preservative in a concentration ranging from 2 to 5 mg/ml.

277219US0PCT Preliminary Amendment

Claim 29 (New): A formulation according to claim 11, comprising the preservative in a concentration at 3 mg/ml.